A burst of innovation in treatments for allergies is particularly good news for adults. We explain why https://t.co/Fz07x1VoaC ...

For common allergens, such as pollen and dust mites, immunotherapy—in the form of drops, shots or tablets—is now highly effective for most people. Progress has been slower for food allergies, but that is changing https://t.co/Ba8Fti6L7t ...

Allergies are on the rise. But treatments allowing people to manage their conditions—even the most dangerous ones—are becoming increasingly effective, accessible and safe https://t.co/DXwG166ycM ...

The 5 Best Hypoallergenic Pillows To Combat Nighttime Allergieshttps://t.co/1exxci8PcU https://t.co/VJUmaroo21 ...

Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the ...